Tolimidone

Drug Profile

Tolimidone

Alternative Names: CP-26154; MLR-1023

Latest Information Update: 24 Jun 2016

Price : $50

At a glance

  • Originator Pfizer
  • Developer Bukwang Pharmaceutical; Melior Pharmaceuticals, Inc.
  • Class Antihyperglycaemics; Phenyl ethers; Small molecules
  • Mechanism of Action Lyn protein-tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 13 Jun 2016 Efficacy and adverse events data from a phase IIa trial in Type-2 diabetes mellitus presented at the 76th Annual Scientific Sessions of the American Diabetes Association (ADA-2016)
  • 01 May 2016 Bukwang Pharmaceutical completes a phase II trial in Type-2 diabetes mellitus in USA and South Korea (PO) (NCT02317796)
  • 15 Mar 2016 Melior Discovery and Bukwang Pharmaceutical plans a phase IIb trial for Type-2 diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top